Please enable JavaScript to continue using this application.

Compare $PLX vs $TRDA | Chartloom

Compare

$PLX vs $TRDA

Protalix Biotherapeutics Inc · Entrada Therapeutics Inc

PLX

Protalix Biotherapeutics Inc

TRDA

Entrada Therapeutics Inc

Compare $PLX vs $TRDA

Comparing Protalix Biotherapeutics Inc and Entrada Therapeutics Inc

PLXProtalix Biotherapeutics Inc

TRDAEntrada Therapeutics Inc

PLXProtalix Biotherapeutics Inc

Market cap

$224M

P/E (TTM)

12.11x

Forward P/E (NTM)

—

Forward P/S (NTM)

3.56x

Rev growth (TTM)

30.1%

YTD performance

59.8%

52W performance

8.2%

FCF yield

3.4%

TRDAEntrada Therapeutics Inc

Market cap

$220M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.15x

Rev growth (TTM)

-94.1%

YTD performance

-43.6%

52W performance

-8.0%

FCF yield

-61.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PLX

TRDA

Detailed metrics comparison

PLX

Protalix Biotherapeutics Inc

TRDA

Entrada Therapeutics Inc

Market Cap

PLX$224M

TRDA$220M

Enterprise Value

PLX$197M

TRDA$121M

Price

PLX$2.78

TRDA$5.67

P/E Ratio

PLX12.11x

TRDAN/A

P/S Ratio

PLX2.78x

TRDA46.97x

EV/Sales

PLX2.44x

TRDA25.79x

EV/EBITDA

PLX7.37x

TRDA15.47x

P/B Ratio

PLX3.06x

TRDA0.90x

P/FCF Ratio

PLX29.21x

TRDAN/A

EV/FCF

PLX25.63x

TRDA-0.89x

PEG Ratio

PLX0.06x

TRDAN/A

Forward P/E (NTM)

PLXN/A

TRDAN/A

Forward P/S (NTM)

PLX3.56x

TRDA5.15x

Revenue (TTM)

PLX$81M

TRDA$5M

Revenue Growth (YoY)

PLX30.1%

TRDA-94.1%

Forward Rev Growth

PLX-19.1%

TRDA124.9%

Gross Margin (TTM)

PLX69.2%

TRDA0.0%

Operating Margin (TTM)

PLX28.9%

TRDA0.0%

EBITDA Margin (TTM)

PLX30.8%

TRDA-3686.8%

Net Margin (TTM)

PLX23.5%

TRDA-3537.7%

FCF Margin (TTM)

PLX9.5%

TRDA-2883.2%

Net Income (TTM)

PLX$19M

TRDA$-166M

FCF (TTM)

PLX$8M

TRDA$-135M

EPS (TTM)

PLX$0.23

TRDA-$3.93

ROE (TTM)

PLX31.6%

TRDA-5761.0%

ROA (TTM)

PLX20.1%

TRDA-4654.0%

ROIC (TTM)

PLX31.6%

TRDA-5761.0%

Cash

PLX$27M

TRDA$99M

Debt

PLX$0

TRDA$0

Net Cash/Debt

PLX$27M

TRDA$99M

Current Ratio (TTM)

PLX2.94x

TRDA10.89x

Quick Ratio (TTM)

PLX1.91x

TRDA10.47x

Debt/Equity (TTM)

PLX0.00x

TRDA0.00x

Debt/Assets (TTM)

PLX0.0%

TRDA0.0%

Interest Coverage (TTM)

PLXN/A

TRDAN/A

Net Debt/EBITDA (TTM)

PLX0.00x

TRDA0.00x

Beta

PLX-0.05

TRDA-0.22

52W Performance

PLX8.2%

TRDA-8.0%

YTD Performance

PLX59.8%

TRDA-43.6%

% from 52W High

PLX-12.9%

TRDA-65.5%

% from 52W Low

PLX73.7%

TRDA10.1%

Asset Turnover (TTM)

PLX0.85x

TRDA0.01x

FCF Yield (TTM)

PLX3.4%

TRDA-61.4%

Earnings Yield (TTM)

PLX8.5%

TRDA-75.3%

Dividend Yield (TTM)

PLXN/A

TRDAN/A

Rule of 40

PLX39.7

TRDA-2,977.3

EV/GP/RG

PLXN/A

TRDAN/A

Ticker research

View PLX research View TRDA research

Metric	PLX Protalix Biotherapeutics Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$224M	$220M
Enterprise Value	$197M	$121M
Price	$2.78	$5.67
P/E Ratio	12.11x	N/A
P/S Ratio	2.78x	46.97x
EV/Sales	2.44x	25.79x
EV/EBITDA	7.37x	15.47x
P/B Ratio	3.06x	0.90x
P/FCF Ratio	29.21x	N/A
EV/FCF	25.63x	-0.89x
PEG Ratio	0.06x	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.56x	5.15x
Revenue & Growth
Revenue (TTM)	$81M	$5M
Revenue Growth (YoY)	30.1%	-94.1%
Forward Rev Growth	-19.1%	124.9%
Profitability
Gross Margin (TTM)	69.2%	0.0%
Operating Margin (TTM)	28.9%	0.0%
EBITDA Margin (TTM)	30.8%	-3686.8%
Net Margin (TTM)	23.5%	-3537.7%
FCF Margin (TTM)	9.5%	-2883.2%
Net Income (TTM)	$19M	$-166M
FCF (TTM)	$8M	$-135M
EPS (TTM)	$0.23	-$3.93
ROE (TTM)	31.6%	-5761.0%
ROA (TTM)	20.1%	-4654.0%
ROIC (TTM)	31.6%	-5761.0%
Financial Health
Cash	$27M	$99M
Debt	$0	$0
Net Cash/Debt	$27M	$99M
Current Ratio (TTM)	2.94x	10.89x
Quick Ratio (TTM)	1.91x	10.47x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.05	-0.22
52W Performance	8.2%	-8.0%
YTD Performance	59.8%	-43.6%
% from 52W High	-12.9%	-65.5%
% from 52W Low	73.7%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.01x
FCF Yield (TTM)	3.4%	-61.4%
Earnings Yield (TTM)	8.5%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	39.7	-2,977.3
EV/GP/RG	N/A	N/A
Ticker research	View PLX research	View TRDA research

Valuation

P/E Ratio

PLX

12.11x

P/S Ratio

PLX

2.78x

TRDA

46.97x

EV/FCF

TRDA

-0.89x

PLX

25.63x

Growth & revenue

Revenue Growth TTM

PLX

30.1%

TRDA

-94.1%

Forward Revenue Growth

TRDA

124.9%

PLX

-19.1%

Profitability & performance

Gross Margin

PLX

69.2%

TRDA

0.0%

ROE

PLX

31.6%

TRDA

-5761.0%

FCF Yield %

PLX

3.4%

TRDA

-61.4%

52-Week Performance

PLX

8.2%

TRDA

-8.0%

Detailed metrics comparison

PLX

Protalix Biotherapeutics Inc

TRDA

Entrada Therapeutics Inc

Market Cap

PLX$224M

TRDA$220M

Enterprise Value

PLX$197M

TRDA$121M

Price

PLX$2.78

TRDA$5.67

P/E Ratio

PLX12.11x

TRDAN/A

P/S Ratio

PLX2.78x

TRDA46.97x

EV/Sales

PLX2.44x

TRDA25.79x

EV/EBITDA

PLX7.37x

TRDA15.47x

P/B Ratio

PLX3.06x

TRDA0.90x

P/FCF Ratio

PLX29.21x

TRDAN/A

EV/FCF

PLX25.63x

TRDA-0.89x

PEG Ratio

PLX0.06x

TRDAN/A

Forward P/E (NTM)

PLXN/A

TRDAN/A

Forward P/S (NTM)

PLX3.56x

TRDA5.15x

Revenue (TTM)

PLX$81M

TRDA$5M

Revenue Growth (YoY)

PLX30.1%

TRDA-94.1%

Forward Rev Growth

PLX-19.1%

TRDA124.9%

Gross Margin (TTM)

PLX69.2%

TRDA0.0%

Operating Margin (TTM)

PLX28.9%

TRDA0.0%

EBITDA Margin (TTM)

PLX30.8%

TRDA-3686.8%

Net Margin (TTM)

PLX23.5%

TRDA-3537.7%

FCF Margin (TTM)

PLX9.5%

TRDA-2883.2%

Net Income (TTM)

PLX$19M

TRDA$-166M

FCF (TTM)

PLX$8M

TRDA$-135M

EPS (TTM)

PLX$0.23

TRDA-$3.93

ROE (TTM)

PLX31.6%

TRDA-5761.0%

ROA (TTM)

PLX20.1%

TRDA-4654.0%

ROIC (TTM)

PLX31.6%

TRDA-5761.0%

Cash

PLX$27M

TRDA$99M

Debt

PLX$0

TRDA$0

Net Cash/Debt

PLX$27M

TRDA$99M

Current Ratio (TTM)

PLX2.94x

TRDA10.89x

Quick Ratio (TTM)

PLX1.91x

TRDA10.47x

Debt/Equity (TTM)

PLX0.00x

TRDA0.00x

Debt/Assets (TTM)

PLX0.0%

TRDA0.0%

Interest Coverage (TTM)

PLXN/A

TRDAN/A

Net Debt/EBITDA (TTM)

PLX0.00x

TRDA0.00x

Beta

PLX-0.05

TRDA-0.22

52W Performance

PLX8.2%

TRDA-8.0%

YTD Performance

PLX59.8%

TRDA-43.6%

% from 52W High

PLX-12.9%

TRDA-65.5%

% from 52W Low

PLX73.7%

TRDA10.1%

Asset Turnover (TTM)

PLX0.85x

TRDA0.01x

FCF Yield (TTM)

PLX3.4%

TRDA-61.4%

Earnings Yield (TTM)

PLX8.5%

TRDA-75.3%

Dividend Yield (TTM)

PLXN/A

TRDAN/A

Rule of 40

PLX39.7

TRDA-2,977.3

EV/GP/RG

PLXN/A

TRDAN/A

Ticker research

View PLX research View TRDA research

Metric	PLX Protalix Biotherapeutics Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$224M	$220M
Enterprise Value	$197M	$121M
Price	$2.78	$5.67
P/E Ratio	12.11x	N/A
P/S Ratio	2.78x	46.97x
EV/Sales	2.44x	25.79x
EV/EBITDA	7.37x	15.47x
P/B Ratio	3.06x	0.90x
P/FCF Ratio	29.21x	N/A
EV/FCF	25.63x	-0.89x
PEG Ratio	0.06x	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.56x	5.15x
Revenue & Growth
Revenue (TTM)	$81M	$5M
Revenue Growth (YoY)	30.1%	-94.1%
Forward Rev Growth	-19.1%	124.9%
Profitability
Gross Margin (TTM)	69.2%	0.0%
Operating Margin (TTM)	28.9%	0.0%
EBITDA Margin (TTM)	30.8%	-3686.8%
Net Margin (TTM)	23.5%	-3537.7%
FCF Margin (TTM)	9.5%	-2883.2%
Net Income (TTM)	$19M	$-166M
FCF (TTM)	$8M	$-135M
EPS (TTM)	$0.23	-$3.93
ROE (TTM)	31.6%	-5761.0%
ROA (TTM)	20.1%	-4654.0%
ROIC (TTM)	31.6%	-5761.0%
Financial Health
Cash	$27M	$99M
Debt	$0	$0
Net Cash/Debt	$27M	$99M
Current Ratio (TTM)	2.94x	10.89x
Quick Ratio (TTM)	1.91x	10.47x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.05	-0.22
52W Performance	8.2%	-8.0%
YTD Performance	59.8%	-43.6%
% from 52W High	-12.9%	-65.5%
% from 52W Low	73.7%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.01x
FCF Yield (TTM)	3.4%	-61.4%
Earnings Yield (TTM)	8.5%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	39.7	-2,977.3
EV/GP/RG	N/A	N/A
Ticker research	View PLX research	View TRDA research